Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Breast Cancer

Free Subscription Articles published in Histopathology Retrieve available abstracts of 48 articles: HTML format

Single Articles

September 2025
1. MAKHLOUF S, Almalki N, Sheha A, Atallah NM, et al
   Outcome prediction of oestrogen receptor-positive breast cancer based on a panel of oestrogen receptor-regulated genes.
   Histopathology. 2025 Sep 12. doi: 10.1111/his.15557.
   PubMed     Abstract available
   
   
   August 2025
2. SALISBURY T, Rendi M, Bhalli R, Bean GR, et al
   DCIS-like invasive carcinoma of the breast with tumour-associated microvasculature mimicking myoepithelium: a diagnostic pitfall.
   Histopathology. 2025;87:246-257.
   PubMed     Abstract available
   
   
   
3. HAN R, Hashmi AA, Wen HY, Murray M, et al
   Clinicopathological features of microinvasive lobular carcinoma.
   Histopathology. 2025;87:235-245.
   PubMed     Abstract available
   
   
   
4. TAN PH, Ellis IO, Allison KH, Badve SS, et al
   Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria.
   Histopathology. 2025;87:169-182.
   PubMed     Abstract available
   
   
   July 2025
5. LEE AHS, Rakha EA, Hodi Z, Abbas A, et al
   Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy.
   Histopathology. 2025;87:58-67.
   PubMed     Abstract available
   
   
   June 2025
6. LAOKULRATH N, Nasir NDM, Gudi M, Tan PH, et al
   Diagnostic accuracy and challenges of intraoperative frozen section evaluation for axillary sentinel lymph node biopsy and breast margins.
   Histopathology. 2025;86:1121-1136.
   PubMed     Abstract available
   
   
   
7. AL-REFAI R, Ali A, Roychoudhury S, Bendari A, et al
   Male breast atypical ductal hyperplasia (ADH): clinicopathological insights from a rare cohort.
   Histopathology. 2025;86:1137-1146.
   PubMed     Abstract available
   
   
   May 2025
8. SOKOLOVA A, Joshi V, Chittoory H, Walsh M, et al
   ROS1 immunohistochemistry as a potential predictive biomarker for ROS1-targeted therapy in breast cancer: impact of antibody clone selection.
   Histopathology. 2025 May 13. doi: 10.1111/his.15465.
   PubMed     Abstract available
   
   
   
9. EL SHEIKH S, Mansour MA, Provenzano E, Shaaban A, et al
   Diagnostic interobserver variability of atypia assessment in columnar cell lesions among a group of expert breast pathologists in the United Kingdom and the Republic of Ireland, on behalf of the UK national coordinating committee for breast pathology.
   Histopathology. 2025;86:953-966.
   PubMed     Abstract available
   
   
   
10. HONG R, Wang H, Lin Y, Yin X, et al
    The clinicopathological and molecular features of primary high-grade neuroendocrine tumour in the breast.
    Histopathology. 2025;86:900-915.
    PubMed     Abstract available
    
    
    April 2025
11. BOYRAZ B, Robinson B, Lindeman N, Hoda SA, et al
    Subareolar sclerosing ductal hyperplasia shows PI3K pathway alterations.
    Histopathology. 2025;86:824-827.
    PubMed     Abstract available
    
    
    
12. KHEDR M, Gandhi S, Roy AM, Alharbi M, et al
    Breast biomarkers evolution between primary and distant metastasis: incidence and significance.
    Histopathology. 2025;86:793-804.
    PubMed     Abstract available
    
    
    
13. KATAYAMA A, Makhlouf S, Toss MS, Oyama T, et al
    Nuclear morphological characterisation of lobular carcinoma variants: a morphometric study.
    Histopathology. 2025;86:813-823.
    PubMed     Abstract available
    
    
    
14. KRINGS G, Shamir ER, Lae M, Bean GR, et al
    Serous-like breast carcinomas: immunophenotypic, genetic, and clinicopathologic characterization of a morphologically distinct group of tumours.
    Histopathology. 2025;86:779-792.
    PubMed     Abstract available
    
    
    
15. YANG E, Fineberg S, Mohamed A, Brogi E, et al
    Variability in the diagnosis and reporting of metaplastic breast carcinoma: results of an international survey.
    Histopathology. 2025;86:742-749.
    PubMed     Abstract available
    
    
    March 2025
16. KIM M, Lee M, Lee A, Choi BO, et al
    Correlating p53 immunostaining patterns with somatic TP53 mutation and functional properties of mutant p53 in triple-negative breast cancer.
    Histopathology. 2025 Mar 31. doi: 10.1111/his.15453.
    PubMed     Abstract available
    
    
    
17. CHAN R, Leung H, Li J, Poon I, et al
    Evaluation of breast-specific marker expression in metastatic breast cancers: Correlation with subtype switch.
    Histopathology. 2025;86:536-546.
    PubMed     Abstract available
    
    
    
18. RAKHA EA, Quinn C
    Controversies regarding encapsulated papillary carcinoma of the breast: an approach to evaluation and categorisation.
    Histopathology. 2025;86:497-513.
    PubMed     Abstract available
    
    
    February 2025
19. AI D, Arrey EN, Postlewait LM, Gao Y, et al
    The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response.
    Histopathology. 2025 Feb 4. doi: 10.1111/his.15417.
    PubMed     Abstract available
    
    
    
20. YANG E, D'Alfonso TM, Morrow M, Brogi E, et al
    Discordance of human epidermal growth factor receptor 2-low status between breast primary and distant metastases with clinical-pathological correlation.
    Histopathology. 2025;86:441-449.
    PubMed     Abstract available
    
    
    
21. TAHA SR, Boulos F
    E-cadherin staining in the diagnosis of lobular versus ductal neoplasms of the breast: the emperor has no clothes.
    Histopathology. 2025;86:327-340.
    PubMed     Abstract available
    
    
    January 2025
22. ASHI A, Awaji AA, Bond J, Johnson CA, et al
    Threonine and tyrosine kinase (TTK) mRNA and protein expression in breast cancer; prognostic significance in the neoadjuvant setting.
    Histopathology. 2025 Jan 7. doi: 10.1111/his.15399.
    PubMed     Abstract available
    
    
    
23. LEE AHS, Hodi Z, Abbas A, Ellis IO, et al
    HER2-positive grade 1 invasive carcinomas of the breast.
    Histopathology. 2025;86:278-284.
    PubMed     Abstract available
    
    
    December 2024
24. WANG Y, Liu L, Graff SL, Cheng L, et al
    Recent advancements in biomarkers and molecular diagnostics in hormonal receptor-positive breast cancer.
    Histopathology. 2024 Dec 17. doi: 10.1111/his.15395.
    PubMed     Abstract available
    
    
    
25. ONAGI H, Horimoto Y, Okano S, Sasa K, et al
    Clinicopathological characteristics of Japanese patients with breast cancer and MET exon 14 skipping alterations.
    Histopathology. 2024 Dec 4. doi: 10.1111/his.15382.
    PubMed     Abstract available
    
    
    
26. HEMPENIUS MA, Eenkhoorn MA, Hoeg H, Dabbs DJ, et al
    Quantitative comparison of immunohistochemical HER2-low detection in an interlaboratory study.
    Histopathology. 2024;85:920-928.
    PubMed     Abstract available
    
    
    October 2024
27. MATSUMOTO H, Miyata R, Tsuruta Y, Nakada N, et al
    Ki-67 evaluation using deep-learning model-assisted digital image analysis in breast cancer.
    Histopathology. 2024 Oct 31. doi: 10.1111/his.15356.
    PubMed     Abstract available
    
    
    
28. WANG Y, Liu L, Graff SL, Cheng L, et al
    Locoregional event or dyssynchronous distant metastasis: clinicopathological and molecular analysis of contralateral axillary lymph node metastasis in breast cancer patients.
    Histopathology. 2024 Oct 22. doi: 10.1111/his.15345.
    PubMed     Abstract available
    
    
    September 2024
29. WONG CJW, Md Nasir ND, Koh VCY, Campbell F, et al
    Mapping the cited evidence of ductal carcinoma in situ from the 5th edition of the World Health Organisation classification of tumours of the breast.
    Histopathology. 2024;85:510-520.
    PubMed     Abstract available
    
    
    
30. BATRA H, Bose PSC, Ding Y, Dai A, et al
    MYB expression by immunohistochemistry is highly specific and sensitive for detection of solid variant of adenoid cystic carcinoma of the breast among all triple-negative breast cancers.
    Histopathology. 2024;85:503-509.
    PubMed     Abstract available
    
    
    
31. TURASHVILI G
    Nonneoplastic and neoplastic sclerosing lesions of the breast.
    Histopathology. 2024;85:383-396.
    PubMed     Abstract available
    
    
    
32. GRABENSTETTER A, Brennan SB, Jochelson MS, Brogi E, et al
    Radial sclerosing lesions found on core needle biopsy: excision can be safely avoided.
    Histopathology. 2024;85:397-404.
    PubMed     Abstract available
    
    
    
33. ELLIS I, Webster F, Allison KH, Dang C, et al
    Dataset for reporting of the invasive carcinoma of the breast: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;85:418-436.
    PubMed     Abstract available
    
    
    August 2024
34. ZWAGER MC, Yu S, Buikema HJ, de Bock GH, et al
    Advancing Ki67 hotspot detection in breast cancer: a comparative analysis of automated digital image analysis algorithms.
    Histopathology. 2024 Aug 5. doi: 10.1111/his.15294.
    PubMed     Abstract available
    
    
    July 2024
35. BANNIER PA, Broeckx G, Herpin L, Dubois R, et al
    Development of a deep-learning model tailored for HER2 detection in breast cancer to aid pathologists in interpreting HER2-low cases.
    Histopathology. 2024 Jul 14. doi: 10.1111/his.15274.
    PubMed     Abstract available
    
    
    
36. TOZBIKIAN G, Bui MM, Hicks DG, Jaffer S, et al
    Best practices for achieving consensus in HER2-low expression in breast cancer: current perspectives from practising pathologists.
    Histopathology. 2024 Jul 8. doi: 10.1111/his.15275.
    PubMed     Abstract available
    
    
    
37. ZHANG H, Finkelman BS, Ettel MG, Velez MJ, et al
    HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
    Histopathology. 2024;85:3-19.
    PubMed     Abstract available
    
    
    June 2024
38. LASHEN AG, Toss M, Miligy I, Rewcastle E, et al
    Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study.
    Histopathology. 2024 Jun 13. doi: 10.1111/his.15234.
    PubMed     Abstract available
    
    
    
39. MILIGY IM, Awasthi R, Mir Y, Khurana A, et al
    Morphological and molecular changes of oestrogen receptor-positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study.
    Histopathology. 2024 Jun 7. doi: 10.1111/his.15238.
    PubMed     Abstract available
    
    
    
40. LAOKULRATH N, Gudi M, Salahuddin SA, Chong APY, et al
    Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges.
    Histopathology. 2024 Jun 6. doi: 10.1111/his.15213.
    PubMed     Abstract available
    
    
    
41. BOSSUYT V, Provenzano E, Symmans WF, Webster F, et al
    A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR).
    Histopathology. 2024;84:1111-1129.
    PubMed     Abstract available
    
    
    May 2024
42. LI J, Dong P, Wang X, Zhang J, et al
    Artificial intelligence enhances whole-slide interpretation of PD-L1 CPS in triple-negative breast cancer: A multi-institutional ring study.
    Histopathology. 2024 May 15. doi: 10.1111/his.15205.
    PubMed     Abstract available
    
    
    
43. HUANG CY, Chang RF, Lin CY, Hsieh MS, et al
    Deep-learning model to improve histological grading and predict upstaging of atypical ductal hyperplasia / ductal carcinoma in situ on breast biopsy.
    Histopathology. 2024;84:983-1002.
    PubMed     Abstract available
    
    
    April 2024
44. BADR NM, Zaakouk M, Zhang Q, Kearns D, et al
    Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist.
    Histopathology. 2024 Apr 23. doi: 10.1111/his.15193.
    PubMed     Abstract available
    
    
    
45. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    PubMed     Abstract available
    
    
    
46. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    PubMed     Abstract available
    
    
    
47. AZAM AS, Tsang YW, Thirlwall J, Kimani PK, et al
    Digital pathology for reporting histopathology samples, including cancer screening samples - definitive evidence from a multisite study.
    Histopathology. 2024;84:847-862.
    PubMed     Abstract available
    
    
    March 2024
48. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.